Cargando…
Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database
BACKGROUND: The utility of hepatitis C virus (HCV) organs has increased after the Food and Drug Administration approval of direct acting anti-viral (DAA) medications for the HCV treatment. The efficacy of DAA in treating HCV is nearly 100%. AIM: To analyze the United Network for Organ Sharing (UNOS)...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157704/ https://www.ncbi.nlm.nih.gov/pubmed/35721288 http://dx.doi.org/10.4254/wjh.v14.i5.984 |
_version_ | 1784718692999757824 |
---|---|
author | Dhaliwal, Amaninder Dhindsa, Banreet Ramai, Daryl Sayles, Harlan Chandan, Saurabh Rangray, Rajani |
author_facet | Dhaliwal, Amaninder Dhindsa, Banreet Ramai, Daryl Sayles, Harlan Chandan, Saurabh Rangray, Rajani |
author_sort | Dhaliwal, Amaninder |
collection | PubMed |
description | BACKGROUND: The utility of hepatitis C virus (HCV) organs has increased after the Food and Drug Administration approval of direct acting anti-viral (DAA) medications for the HCV treatment. The efficacy of DAA in treating HCV is nearly 100%. AIM: To analyze the United Network for Organ Sharing (UNOS) database to compare the survival rates between the hepatitis C positive donors and negative recipients and hepatitis C negative donors and recipients. METHODS: We analyzed the adult patients in UNOS database who underwent deceased donor liver transplant from January 2014 to December 2017. The primary endpoint was to compare the survival rates among the four groups with different hepatitis C donor and recipient status: (Group 1) Both donor and recipient negative for HCV (Group 2) Negative donor and positive recipient for HCV (Group 3) Positive donor and negative recipient for HCV (Group 4) Both positive donor and recipient for HCV. SAS 9.4 software was used for the data analysis. Kaplan Meier log rank test was used to analyze the estimated survival rates among the four groups. RESULTS: A total of 24512 patients were included: Group 1: 16436, Group 2: 6174, Group 3: 253 and Group 4: 1649. The 1-year (Group 1: 91.8%, Group 2: 92.12%, Group 3: 87%, Group 4: 92.8%), 2-year (Group 1: 88.4%, Group 2: 88.1%, Group 3: 84.3%, Group 4: 87.5%), 3-year (Group 1: 84.9%, Group 2: 84.3%, Group 3: 75.9%, Group 4: 83.2%) survival rates showed no statistical significance among the four groups. Kaplan Meier log rank test did not show any statistical significance difference in the estimated survival rates between Group 3 vs all the other groups. CONCLUSION: The survival rates in hepatitis C positive donors and negative recipients are similar as compared to both hepatitis C negative donors and recipients. This could be due to the use of DAA therapy with cure rates of nearly 100%. This study supports the use of hepatitis C positive organs in the selected group of recipients with and without HCV infection. Further long-term studies are needed to further validate these findings. |
format | Online Article Text |
id | pubmed-9157704 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-91577042022-06-17 Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database Dhaliwal, Amaninder Dhindsa, Banreet Ramai, Daryl Sayles, Harlan Chandan, Saurabh Rangray, Rajani World J Hepatol Retrospective Study BACKGROUND: The utility of hepatitis C virus (HCV) organs has increased after the Food and Drug Administration approval of direct acting anti-viral (DAA) medications for the HCV treatment. The efficacy of DAA in treating HCV is nearly 100%. AIM: To analyze the United Network for Organ Sharing (UNOS) database to compare the survival rates between the hepatitis C positive donors and negative recipients and hepatitis C negative donors and recipients. METHODS: We analyzed the adult patients in UNOS database who underwent deceased donor liver transplant from January 2014 to December 2017. The primary endpoint was to compare the survival rates among the four groups with different hepatitis C donor and recipient status: (Group 1) Both donor and recipient negative for HCV (Group 2) Negative donor and positive recipient for HCV (Group 3) Positive donor and negative recipient for HCV (Group 4) Both positive donor and recipient for HCV. SAS 9.4 software was used for the data analysis. Kaplan Meier log rank test was used to analyze the estimated survival rates among the four groups. RESULTS: A total of 24512 patients were included: Group 1: 16436, Group 2: 6174, Group 3: 253 and Group 4: 1649. The 1-year (Group 1: 91.8%, Group 2: 92.12%, Group 3: 87%, Group 4: 92.8%), 2-year (Group 1: 88.4%, Group 2: 88.1%, Group 3: 84.3%, Group 4: 87.5%), 3-year (Group 1: 84.9%, Group 2: 84.3%, Group 3: 75.9%, Group 4: 83.2%) survival rates showed no statistical significance among the four groups. Kaplan Meier log rank test did not show any statistical significance difference in the estimated survival rates between Group 3 vs all the other groups. CONCLUSION: The survival rates in hepatitis C positive donors and negative recipients are similar as compared to both hepatitis C negative donors and recipients. This could be due to the use of DAA therapy with cure rates of nearly 100%. This study supports the use of hepatitis C positive organs in the selected group of recipients with and without HCV infection. Further long-term studies are needed to further validate these findings. Baishideng Publishing Group Inc 2022-05-27 2022-05-27 /pmc/articles/PMC9157704/ /pubmed/35721288 http://dx.doi.org/10.4254/wjh.v14.i5.984 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Retrospective Study Dhaliwal, Amaninder Dhindsa, Banreet Ramai, Daryl Sayles, Harlan Chandan, Saurabh Rangray, Rajani Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database |
title | Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database |
title_full | Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database |
title_fullStr | Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database |
title_full_unstemmed | Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database |
title_short | Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database |
title_sort | impact of utilization of hepatitis c positive organs in liver transplant: analysis of united network for organ sharing database |
topic | Retrospective Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157704/ https://www.ncbi.nlm.nih.gov/pubmed/35721288 http://dx.doi.org/10.4254/wjh.v14.i5.984 |
work_keys_str_mv | AT dhaliwalamaninder impactofutilizationofhepatitiscpositiveorgansinlivertransplantanalysisofunitednetworkfororgansharingdatabase AT dhindsabanreet impactofutilizationofhepatitiscpositiveorgansinlivertransplantanalysisofunitednetworkfororgansharingdatabase AT ramaidaryl impactofutilizationofhepatitiscpositiveorgansinlivertransplantanalysisofunitednetworkfororgansharingdatabase AT saylesharlan impactofutilizationofhepatitiscpositiveorgansinlivertransplantanalysisofunitednetworkfororgansharingdatabase AT chandansaurabh impactofutilizationofhepatitiscpositiveorgansinlivertransplantanalysisofunitednetworkfororgansharingdatabase AT rangrayrajani impactofutilizationofhepatitiscpositiveorgansinlivertransplantanalysisofunitednetworkfororgansharingdatabase |